Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (surpass-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 surpass-3 trial
November 9, 2021
Whether the lower price represents a bargain or wasted money depends entirely on whether the product does anything, and the data says it does not
Fat-dissolving treatments are quickly becoming a favorite among those looking for non-surgical ways to contour their bodies
Then, the FDA declared in late 2024 that tirzepatide was no longer in shortage, and it determined that semaglutide was no longer in shortage in early 2025
Retatrutide stands out here, as it activates three receptors: GLP-1, GIP, and glucagon